Pharma Major-Sanofi India Reports 8 Per Cent Growth in Q4 2024 Net Sales Amid Strategic Demerger Pharma Major-Sanofi India Reports 8 Per Cent Growth in Q4 2024 Net Sales Amid Strategic Demerger Total revenue from operations for the full year 2024 was Rs 2,013.2 crore, showing a slight increase from Rs 1,996.1 crore in 2023. Kiran Shroff / Friday, February 28, 2025 / Article rating: 5.0 The company has maintained a final dividend of Rs 117 per equity share, subject to shareholder approval.
Rs 500 Crore Green Energy Deal! A New Solar Giant Partners with Assam Rs 500 Crore Green Energy Deal! A New Solar Giant Partners with Assam A leading renewable energy company joins forces with Assam to develop large-scale solar and battery storage projects. Pushkar Shinde / Friday, February 28, 2025 / Article rating: 4.2 A leading renewable energy company joins forces with Assam to develop large-scale solar and battery storage projects.
Solar Solutions Provider & CIMSME Launch User-Friendly Mobile App, Accelerating 1 Lakh Solar Home Target by 2026 Solar Solutions Provider & CIMSME Launch User-Friendly Mobile App, Accelerating 1 Lakh Solar Home Target by 2026 The stock is up over 58 per cent from its 52-week low of Rs 73.50 per share and delivered multibagger returns of over 8,600 per cent in 5 years. Kiran Shroff / Friday, February 28, 2025 / Article rating: 5.0 The stock is up over 58 per cent from its 52-week low of Rs 73.50 per share and delivered multibagger returns of over 8,600 per cent in 5 years.
Bloodbath on Dalal Street: Sensex & Nifty 50 Plunge, Broader Indices Suffer Steep Losses Bloodbath on Dalal Street: Sensex & Nifty 50 Plunge, Broader Indices Suffer Steep Losses The Nifty 50 has plummeted by 1.17 per cent to 22,281.65, and the Sensex has fallen by 1.27 per cent to 73,665.90. Manoj Reddy Sama / Friday, February 28, 2025 / Article rating: 5.0 Market breadth is extremely negative, with 211 advances and 2,199 declines, indicating a severe negative sentiment prevailing among investors.
Top three stocks that saw heavy demand from buyers in the pre-opening session today Top three stocks that saw heavy demand from buyers in the pre-opening session today These three stocks were the top gainers on BSE in the pre-opening session today. Prajwal Wakhare / Friday, February 28, 2025 / Article rating: 3.7
February 28: Key Market Updates Before Opening Bell February 28: Key Market Updates Before Opening Bell The GIFT Nifty hovered around 22,532 early in the morning, signaling a flat-to-muted opening for domestic equities. Manoj Reddy Sama / Friday, February 28, 2025 / Article rating: 5.0 The S&P 500 slid 1.59 per cent to finish at 5,861.57, while the Nasdaq took a steep 2.78 per cent hit, closing at 18,544.42.
Part 2: Understanding Mutual Fund Taxation - Equity, Debt and Hybrid Mutual Funds Part 2: Understanding Mutual Fund Taxation - Equity, Debt and Hybrid Mutual Funds This article explains the taxation of equity, debt, and hybrid mutual funds post-Budget 2024, covering long-term and short-term capital gains, indexation benefits, and tax planning. Prajwal Wakhare / Thursday, February 27, 2025 / Article rating: 5.0
Price Volume breakout stocks: These stocks likely to be in focus tomorrow! Price Volume breakout stocks: These stocks likely to be in focus tomorrow! Top 3 price-volume breakout stocks Prajwal Wakhare / Thursday, February 27, 2025 / Article rating: 3.2
Bandhan Bank Surges as RBI Eases Risk-Weight Norms for Loans to NBFCs Bandhan Bank Surges as RBI Eases Risk-Weight Norms for Loans to NBFCs RBI’s Policy Reversal to Boost Credit Flow, Strengthen Microfinance Lenders Abhishek Wani / Thursday, February 27, 2025 / Article rating: 3.0 RBI’s Policy Reversal to Boost Credit Flow, Strengthen Microfinance Lenders
FIIs Favourite: Caplin Steriles Secures US FDA Approval, FIIs Stake Rises to 4.86 per cent FIIs Favourite: Caplin Steriles Secures US FDA Approval, FIIs Stake Rises to 4.86 per cent Caplin Point Laboratories has demonstrated robust financial performance in recent quarters. The company reported revenue of Rs 1,523 crore for Q3 FY25, which is equivalent to its full-year revenue in FY23. Abhishek Wani / Thursday, February 27, 2025 / Article rating: 4.7 Caplin Point Laboratories has demonstrated robust financial performance in recent quarters. The company reported revenue of Rs 1,523 crore for Q3 FY25, which is equivalent to its full-year revenue in FY23.